GWM
SVA

Geneos Wealth Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Geneos Wealth Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-150
Closed -$1K – 2492
2018
Q4 		$1K Hold
150
– – ﹤0.01% 2374
2018
Q3 		$1K Hold
150
– – ﹤0.01% 2403
2018
Q2 		$1K Hold
150
– – ﹤0.01% 2250
2018
Q1 		$1K Hold
150
– – ﹤0.01% 2161
2017
Q4 		$1K Hold
150
– – ﹤0.01% 2162
2017
Q3 		$1K Hold
150
– – ﹤0.01% 2111
2017
Q2 		$1K Buy
+150
New +$822 ﹤0.01% 2064

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RQS
Ramsey Quantitative Systems Louisville, Kentucky $112M AUM 16.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geneos Wealth Management's SVA Position: Q1 2019 in Review

Geneos Wealth Management sold out of Sinovac Biotech, Ltd (SVA) in Q1 2019, closing a stake of 150 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in SVA in Q2 2017 and held it in 7 quarters. The position peaked at $1K in Q4 2018. 25 funds tracked by Wall St. Rank hold SVA as of Q1 2019.

  • Geneos Wealth Management reported no remaining Sinovac Biotech, Ltd position as of Q1 2019 after selling out during the quarter.
  • Geneos Wealth Management sold 150 Sinovac Biotech, Ltd shares in Q1 2019, an estimated $1K.
  • Geneos Wealth Management first reported a position in Sinovac Biotech, Ltd in Q2 2017 and held it in 7 quarters.
  • Geneos Wealth Management's Sinovac Biotech, Ltd position peaked at $1K in Q4 2018.
  • 25 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2019.

Based on Geneos Wealth Management's 13F filing for Q1 2019, filed 7 Sep 2021.